The store will not work correctly when cookies are disabled.
1-methyl-7-nitro-4-(5-(piperidin-1-yl)pentyl)-3,4-dihydroquinoxalin-2(1H)-one
ID: ALA2079504
PubChem CID: 70694536
Max Phase: Preclinical
Molecular Formula: C19H28N4O3
Molecular Weight: 360.46
Molecule Type: Small molecule
Associated Items:
Names and Identifiers
Canonical SMILES: CN1C(=O)CN(CCCCCN2CCCCC2)c2ccc([N+](=O)[O-])cc21
Standard InChI: InChI=1S/C19H28N4O3/c1-20-18-14-16(23(25)26)8-9-17(18)22(15-19(20)24)13-7-3-6-12-21-10-4-2-5-11-21/h8-9,14H,2-7,10-13,15H2,1H3
Standard InChI Key: QQFYJLGIQOPALN-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 28 0 0 0 0 0 0 0 0999 V2000
7.7777 -18.6125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7766 -19.4398 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.4914 -19.8527 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.4896 -18.1997 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.2050 -18.6088 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.2084 -19.4373 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.9236 -19.8463 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
10.6400 -19.4314 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.6366 -18.6030 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.9168 -18.1894 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
7.0625 -18.2004 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.3481 -18.6131 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
7.0623 -17.3754 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
9.9258 -20.6713 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.6414 -21.0819 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.3548 -20.6675 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.0704 -21.0780 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.7837 -20.6636 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.4993 -21.0741 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
13.4958 -21.8965 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.2072 -22.3070 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.9230 -21.8960 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.9228 -21.0701 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.2067 -20.6550 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.3498 -18.1883 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
9.9123 -17.3644 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11 13 1 0
1 11 1 0
3 6 2 0
7 14 1 0
1 2 2 0
14 15 1 0
5 4 2 0
15 16 1 0
4 1 1 0
16 17 1 0
5 10 1 0
17 18 1 0
6 7 1 0
18 19 1 0
19 20 1 0
7 8 1 0
8 9 1 0
9 10 1 0
5 6 1 0
19 24 1 0
20 21 1 0
21 22 1 0
22 23 1 0
23 24 1 0
2 3 1 0
9 25 2 0
11 12 2 0
10 26 1 0
M CHG 2 11 1 13 -1
M END
Associated Targets(non-human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 360.46 | Molecular Weight (Monoisotopic): 360.2161 | AlogP: 3.03 | #Rotatable Bonds: 7 |
Polar Surface Area: 69.93 | Molecular Species: BASE | HBA: 5 | HBD: ┄ |
#RO5 Violations: ┄ | HBA (Lipinski): 7 | HBD (Lipinski): ┄ | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: ┄ | CX Basic pKa: 9.94 | CX LogP: 2.72 | CX LogD: 0.22 |
Aromatic Rings: 1 | Heavy Atoms: 26 | QED Weighted: 0.42 | Np Likeness Score: -1.22 |
References
1. Jiang X, Wu K, Bai R, Zhang P, Zhang Y.. (2022) Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities., 229 [PMID:34998058] [10.1016/j.ejmech.2021.114085] |